Juvenescence successfully completes Phase 1 clinical trial of PAI-1 inhibitor and strengthens clinical development leadership [Yahoo! Finance]
Johnson & Johnson (JNJ)
Last johnson & johnson earnings: 4/14 06:31 am
Check Earnings Report
US:NYSE Investor Relations:
jnj.com
Company Research
Source: Yahoo! Finance
Phase 2 proof-of-concept trial planned for 2026 in patients with metabolic and fibrotic disease Carmel Nanthakumar, PhD, joins as VP, Translational Biology, following recent appointments of Paul Russell as Chief Development Officer and Catherine McClinton as Head of Clinical Operations Ramsey, Isle of Man, 26 February 2026: Juvenescence Limited, a clinical stage AI-enabled biotech company, today announces that its plasminogen activator inhibitor-1 (PAI-1 inhibitor) (MDI-2517) has successfully completed a Phase 1 trial. The Company has also strengthened its clinical development leadership team with the appointment of Carmel Nanthakumar, PhD, as VP, Translational Biology. In January 2026, Juvenescence's small molecule PAI-1 inhibitor completed a randomized, double-blind, placebo-controlled Phase 1 trial, demonstrating a good safety and tolerability profile and a once-daily profile. This first-in-class treatment is a potent small molecule inhibitor of PAI-1, a key regulator of pro-
Show less
Read more
Impact Snapshot
Event Time:
JNJ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
JNJ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
JNJ alerts
High impacting Johnson & Johnson news events
Weekly update
A roundup of the hottest topics
JNJ
News
- Johnson And Johnson Faces Fresh Talc Verdict As Pipeline Story Evolves [Yahoo! Finance]Yahoo! Finance
- AstraZeneca News On Cancer And Asthma Raises New Questions For Investors [Yahoo! Finance]Yahoo! Finance
- Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancer [Yahoo! Finance]Yahoo! Finance
- Early study results from Johnson & Johnson show promising antitumor activity with combination of pasritamig and docetaxel in advanced prostate cancerPR Newswire
- Are You Looking for a High-Growth Dividend Stock? [Yahoo! Finance]Yahoo! Finance
JNJ
Earnings
- 1/21/26 - Beat
JNJ
Sec Filings
- 2/23/26 - Form 4
- 2/20/26 - Form 144
- 2/18/26 - Form 4
- JNJ's page on the SEC website